| 1001 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
62 |
| 1002 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
66 |
| 1003 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
55 |
| 1004 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Poland |
60 |
| 1005 |
Apheresis |
Allogeneic |
Fanconi's Anemia |
Hematology |
2025 |
Standard Therapy |
Ukraine |
6 |
| 1006 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
69 |
| 1007 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Lithuania |
54 |
| 1008 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Macedonia |
56 |
| 1009 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
CROATIA |
64 |
| 1010 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
75 |
| 1011 |
Apheresis |
Allogeneic |
T-cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
NETHERLANDS |
65 |
| 1012 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
65 |
| 1013 |
Apheresis |
Allogeneic |
Myeloid Sarcoma |
Hematology |
2025 |
Standard Therapy |
Brazil |
48 |
| 1014 |
Apheresis |
Allogeneic |
T-cell Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
17 |
| 1015 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
13 |
| 1016 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2025 |
Standard Therapy |
USA |
69 |
| 1017 |
Apheresis |
Allogeneic |
T-cell Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
13 |
| 1018 |
Apheresis |
Allogeneic |
B-cell Precursor Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Slovakia |
67 |
| 1019 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
72 |
| 1020 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
52 |
| 1021 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Belgium |
64 |
| 1022 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Italy |
68 |
| 1023 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Canada |
56 |
| 1024 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
64 |
| 1025 |
Apheresis |
Allogeneic |
Other Myelofibrosis/Myelosclerosis |
Hematology |
2025 |
Standard Therapy |
USA |
55 |
| 1026 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
64 |
| 1027 |
Apheresis |
Allogeneic |
Myelodysplastic disorder |
Hematology |
2025 |
Standard Therapy |
France |
63 |
| 1028 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
63 |
| 1029 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
20 |
| 1030 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
23 |
| 1031 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
73 |
| 1032 |
Apheresis |
Allogeneic |
Inherited Immune System Disorder |
Hematology |
2025 |
Standard Therapy |
France |
9 |
| 1033 |
Apheresis |
Allogeneic |
Lymphoma – DLBCL |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
55 |
| 1034 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
61 |
| 1035 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Lithuania |
58 |
| 1036 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
73 |
| 1037 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
35 |
| 1038 |
Apheresis |
Allogeneic |
Chronic myelomonocytic leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
65 |
| 1039 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
70 |
| 1040 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
66 |
| 1041 |
Apheresis |
Autologous |
Diffuse large B-cell lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
42 |
| 1042 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Netherlands |
65 |
| 1043 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
60 |
| 1044 |
Apheresis |
Allogeneic |
Post Mielofibrosis |
Hematology |
2025 |
Standard Therapy |
Poland |
66 |
| 1045 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
74 |
| 1046 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
17 |
| 1047 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
72 |
| 1048 |
Apheresis |
Allogeneic |
T-cell prolymphocytic leukemia |
Hematology |
2025 |
Standard Therapy |
New Zealand |
64 |
| 1049 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
62 |
| 1050 |
Apheresis |
Allogeneic |
Mielofibrosis |
Hematology |
2025 |
Standard Therapy |
Finland |
68 |
| 1051 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
35 |
| 1052 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
34 |
| 1053 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Belgium |
63 |
| 1054 |
Apheresis |
Allogeneic |
Mielodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Poland |
72 |
| 1055 |
Apheresis |
Allogeneic |
Mielodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Switzerland |
69 |
| 1056 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
52 |
| 1057 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
26 |
| 1058 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
50 |
| 1059 |
Apheresis |
Allogeneic |
Chronic Lymphocyte Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
71 |
| 1060 |
Apheresis |
Allogeneic |
Anaplastic Large Cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
3 |
| 1061 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
71 |
| 1062 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
29 |
| 1063 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Ukraine |
38 |
| 1064 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
28 |
| 1065 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
46 |
| 1066 |
Apheresis |
Allogeneic |
Hodking lymphoma |
Hematology |
2025 |
Standard Therapy |
Spain |
28 |
| 1067 |
Apheresis |
Allogeneic |
Mielodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Slovakia |
52 |
| 1068 |
Apheresis |
Allogeneic |
T-NHL Angioimmunoblastic T-cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
56 |
| 1069 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
71 |
| 1070 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
23 |
| 1071 |
Apheresis |
Allogeneic |
Mielodysplastic syndrome |
Hematology |
2025 |
Standard Therapy |
Spain |
69 |
| 1072 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Brazil |
71 |
| 1073 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
36 |
| 1074 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
58 |
| 1075 |
Apheresis |
Allogeneic |
Mielodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
68 |
| 1076 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
61 |
| 1077 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
35 |
| 1078 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
39 |
| 1079 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Serbia |
58 |
| 1080 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
USA |
47 |
| 1081 |
Apheresis |
Allogeneic |
Mielodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Netherlands |
62 |
| 1082 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
69 |
| 1083 |
Apheresis |
Allogeneic |
T-cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
35 |
| 1084 |
Apheresis |
Autologous |
Central Nervous System Lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
71 |
| 1085 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
70 |
| 1086 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
61 |
| 1087 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
71 |
| 1088 |
Apheresis |
Autologous |
T-cell lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
39 |
| 1089 |
Apheresis |
Autologous |
Primary central nervous system lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
64 |
| 1090 |
Apheresis |
Allogeneic |
Myelodysplastic syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
56 |
| 1091 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
65 |
| 1092 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Germany |
65 |
| 1093 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
60 |
| 1094 |
Apheresis |
Autologous |
Hodgkin lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
32 |
| 1095 |
Apheresis |
Allogeneic |
Myelodysplastic syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
67 |
| 1096 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
56 |
| 1097 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Columbia |
62 |
| 1098 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
46 |
| 1099 |
Apheresis |
Allogeneic |
Mielodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
66 |
| 1100 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
46 |